Neurotensin Branched Peptide as a Tumor-Targeting Agent for Human Bladder Cancer

Table 1

Clinical features of bladder tumor samples.

Entry	Gender	Age	Type		TNM
1	M	72	Urothelial carcinoma	2,2	T2
2	M	82	Small cell carcinoma	7,5	T3b Nx Mx
3	M	66	Urothelial carcinoma	7,6	T3a N0 Mx
4	M	72	Urothelial carcinoma	2,8	T3a N0 Mx
5	M	55	Urothelial carcinoma	1,7	T2a N0 Mx
6	M	85	Urothelial carcinoma	2,3	Tx N1 Mx
7	F	80	Urothelial carcinoma	2,7	T4 Nx Mx
8	M	83	Urothelial carcinoma	1,1	T2b N0 Mx
9	M	83	Urothelial carcinoma	1,1	T2a N0 Mx
10	M	71	Urothelial carcinoma	2	T2
11	M	60	In situ carcinoma	4,4	Tis Nx Mx
12	M	81	Urothelial carcinoma	3,9	Ta Nx Mx
13	M	52	Urothelial carcinoma	2,2	Ta Nx Mx
14	M	72	Urothelial carcinoma	2,7	T1
15	M	73	Urothelial carcinoma	2,7	T2b N0 Mx
16	M	73	Urothelial carcinoma	1,2	T2b N0 Mx

ratio was calculated on the median of (tumor) and (healthy) RGB values.